Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

A drug repurposing method based on inhibition effect on gene regulatory network

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Integrated edge information and pathway topology for drug-disease associations

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Pathway-Based Drug Repurposing with DPNetinfer: A Method to Predict Drug-Pathway Associations Via Network-Based Approaches.

DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing

Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network

DrugRepPT: a Deep Pre-Training and Fine-Tuning Framework for Drug Repositioning Based on Drug's Expression Perturbation and Treatment Effectiveness.

deepDR: a network-based deep learning approach to in silico drug repositioning

Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.

Prioritization of Candidate Cancer Drugs Based on a Drug Functional Similarity Network Constructed by Integrating Pathway Activities and Drug Activities

Drug Repurposing Based on Drug-Drug Interaction

DrugReSC: targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer

Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression

Computationally repurposing drugs for breast cancer subtypes using a network-based approach

Drug Repositioning By Kernel-Based Integration Of Molecular Structure, Molecular Activity, And Phenotype Data

Informatics on Drug Repurposing for Breast Cancer.

DR3E-Net: Drug Repurposing Network Framework Based on Deep Embedding, Differentially Expressed Genes, and Drug Side Effects